A randomized, open label study to compare the effect of combination treatment with PEGASYS + adefovir dipivoxil versus PEGASYS monotherapy on HBV-DNA and ALT levels in patients with HBeAg-negative, chronic hepatitis B.

Trial Profile

A randomized, open label study to compare the effect of combination treatment with PEGASYS + adefovir dipivoxil versus PEGASYS monotherapy on HBV-DNA and ALT levels in patients with HBeAg-negative, chronic hepatitis B.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Adefovir dipivoxil; Peginterferon alfa-2a
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Acronyms ADVANCE
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Sep 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 19 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top